FDA backs 3 psychedelic drug studies for mental illness
Ella Ruder / beckershospitalreview - The FDA is issuing national priority vouchers to three companies studying psychedelic drugs to treat serious mental illness. The vouchers were issued to companies studying psilocybin for treatment-resistant depression and major depressive disorder as well…
AI Summary: The FDA announced a targeted push to accelerate clinical research into psychedelics for mental illness, issuing three commissioner vouchers to support rigorous trials of psychedelic therapies. The move aims to fast-track evidence generation under regulatory oversight, signalling growing agency willingness to explore unconventional treatments while keeping safety and trial standards squarely in view.
- FDA voucher push and federal policy shift (5)
- Psilocybin and brain science (4)
- Real-world use, safety and clinical readiness (3)
- All Other Stories
FDA voucher push and federal policy shift
Psilocybin and brain science
Real-world use, safety and clinical readiness
All Other Stories
CMS, FDA announce new program to speed up Medicare coverage of breakthrough medical devices
fiercehealthcare - The Trump administration unveiled a new program to speed up Medicare coverage for breakthrough devices, touting that the new pathway cuts red tape for medical device companies to gain reimbursement. CMS said it will pause the existing TCET pathway.
AI Summary: CMS and the Food and Drug Administration launched a coordinated program to accelerate Medicare coverage for breakthrough medical devices, aiming to shorten the gap between regulatory approval and patient access. The initiative aligns agency review processes, defines eligibility, and seeks faster coverage decisions while maintaining safety and evidentiary standards.
- New imaging and monitoring devices promise faster, remote patient care. (3)
- On scene: agencies align to speed device approvals and coverage. (6)
New imaging and monitoring devices promise faster, remote patient care.
On scene: agencies align to speed device approvals and coverage.
Flagging first-quarter volumes dragged CHS’ earnings
Sydney Halleman / healthcaredive - Executives said consumer fears and aggressive denials from payers fueled declining volumes in the quarter, which led CHS to a $58 million loss. Still, the hospital operator said it expects volumes to pick up in the back half of the year.
AI Summary: Community Health Systems reported first-quarter earnings pressured by a steep drop in patient volumes, blaming a surge in payer preauthorization denials for the decline. Executives say the volume shortfall materially weighed on revenue and margins, underscoring how administrative friction between providers and payers can quickly translate into financial pain for hospital operators.
- CHS Q1: earnings hit by volume drops, blame on payers (4)
- Hospitals fight denials: startups, RCM shifts and C-suite focus (4)
- Medicare AI prior authorization pilot causing care delays (3)
- Payers move to standardize prior auth; Congress weighs in (4)
- All Other Stories
CHS Q1: earnings hit by volume drops, blame on payers
Hospitals fight denials: startups, RCM shifts and C-suite focus
Medicare AI prior authorization pilot causing care delays
Payers move to standardize prior auth; Congress weighs in
All Other Stories
Gene therapy improves hearing in 90% of patients with inherited deafness in largest trial of its kind
livescience - A new gene therapy tested in China has improved the hearing of 38 people who were born deaf due to mutations in a gene called OTOF.
AI Summary: A gene therapy for inherited deafness delivered dramatic results, restoring hearing in roughly 90% of treated patients in the largest trial of its kind. Investigators report durable improvements over follow-up, signaling a potential one-time intervention for certain genetic deafness types and challenging the notion that auditory loss is always irreversible. Hope, meet hard data.
- FDA approves first-ever gene therapy for inherited hearing loss (6)
- Primate study finds human-like genetic cause of blindness (1)
- Trial shows durable hearing restored in most patients (3)
FDA approves first-ever gene therapy for inherited hearing loss
Primate study finds human-like genetic cause of blindness
Trial shows durable hearing restored in most patients
FDA approves 1st 2-drug HIV treatment
Ella Jeffries / beckershospitalreview - The FDA has approved Merck’s once-daily, two-drug regimen for adults with virologically suppressed HIV-1. The treatment combines 100 mg doravirine and 0.25 mg islatravir and is indicated for patients with no history of virologic treatment failure and no k…
AI Summary: The FDA has approved Merck’s once‑daily two‑drug antiretroviral regimen, marking a notable market entrant poised to compete with established single‑pill therapies. Regulators cleared the novel combination on efficacy and safety data, setting up potential shifts in prescribing, pricing and competition — and giving Gilead something new to grumble about.
CMS delays Part D GLP-1 model amid skepticism from insurers
fiercehealthcare - The Trump administration is delaying a voluntary model that aimed to expand access to GLP-1s in Part D after pushback from insurers.
AI Summary: Federal regulators have paused a Medicare Part D pilot to expand coverage for GLP‑1 weight‑loss drugs amid payer skepticism and implementation concerns. The delay reflects worries about cost, program design and insurer buy‑in, forcing policymakers to revisit the model while patients and providers wait for clarity on whether Medicare will shoulder these high‑price therapies.
- CMS pauses Medicare GLP‑1 BALANCE pilot amid insurer pushback (4)
- Researchers chase GLP‑1 benefits, from gene therapy to Alzheimer’s (6)
- Telehealth and clinics scale GLP‑1 access, delivery and monitoring (3)
- All Other Stories
CMS pauses Medicare GLP‑1 BALANCE pilot amid insurer pushback
Researchers chase GLP‑1 benefits, from gene therapy to Alzheimer’s
Telehealth and clinics scale GLP‑1 access, delivery and monitoring
All Other Stories
UK passes bill that will eventually ban cigarette purchases
abcnews - Parliament has passed a bill to make cigarettes inaccessible to future generations in the U.K. Children born after December 31, 2008, will never be able to buy cigarettes under the new Tobacco and Vapes Bill
AI Summary: The UK has passed legislation phasing out tobacco sales for younger generations, effectively banning cigarette purchases for people born after 2008. The law creates a rolling age‑based prohibition aimed at cutting smoking initiation and long‑term health harms, while stirring debate over enforcement, retail impact and the practicalities of turning childhood prevention into adult policy.
- Explainers and advocacy for the Tobacco and Vapes Bill (4)
- Health context: cancer burden and treatment equity (3)
- Parliament approves smoking ban for future generations (4)
- All Other Stories
Explainers and advocacy for the Tobacco and Vapes Bill
Health context: cancer burden and treatment equity
Parliament approves smoking ban for future generations
All Other Stories
340B drug discounts are drifting from patients to profit, and reform is now on the table
medicalxpress - The 340B Drug Pricing Program must be reformed to better patient health and disincentivize institutional profit-seeking behaviors, says the American College of Physicians (ACP). In a new policy, "Reforming 340B to Promote Program Integrity and Better Serv…
AI Summary: The 340B drug-discount program is under renewed scrutiny after analyses and advocacy groups argue discounts intended to help patients are instead boosting institutional margins. Hospitals, provider groups and the AHA are contesting HRSA proposals and court rulings, sparking policy debates and potential regulatory fixes to curb markups and steer savings back to vulnerable patients.
CMS to require states to audit Medicaid providers
Kristin Kuchno / beckershospitalreview - CMS Administrator Mehmet Oz, MD, said his administration will require all states to audit healthcare providers to address alleged Medicaid fraud, Politico reported April 21. Dr. Oz unveiled the plan at Politico’s Health Care Summit. Beginning this week, C…
AI Summary: CMS is requiring states to audit Medicaid providers as part of a new oversight initiative aimed at tightening program integrity and provider revalidation. The policy has sparked high‑level calls for nationwide reviews and a proposed 50‑state audit effort, signaling heightened federal scrutiny and potential changes to enrollment, billing and provider eligibility processes.
UnitedHealth Group boosts 2026 outlook as it posts Q1 earnings, revenue beat
fiercehealthcare - UnitedHealth Group is boosting its 2026 outlook after seeing some payoff to its efforts to control medical costs.
AI Summary: UnitedHealth reported stronger‑than‑expected first‑quarter results and upgraded its 2026 profit outlook, citing operational momentum and pricing moves that buoyed investor confidence. Coverage also captures contrasting takes on quarterly performance and the insurer’s ongoing strategy to reclaim margin, signaling a company shifting from defense to offense in a softening healthcare market.
- Earnings beat: UnitedHealth posts Q1 strength, raises 2026 outlook (3)
- Margin playbook: member cuts, buybacks, and broker pressures (3)
- Optum tech and exec pay: AI bets and compensation scrutiny (4)
- All Other Stories
Earnings beat: UnitedHealth posts Q1 strength, raises 2026 outlook
Margin playbook: member cuts, buybacks, and broker pressures
Optum tech and exec pay: AI bets and compensation scrutiny
All Other Stories
RFK Jr. says China is 'eating our lunch' in biotech advances
Zachary Brennan / endpoints - China is "eating our lunch" on new drug approvals and clinical trial starts, HHS Secretary Robert F. Kennedy Jr. told Congress Tuesday, while praising the FDA's actions so far. "We are losing scientists, we're losing ...
AI Summary: Robert F. Kennedy Jr. publicly criticized U.S. biotech competitiveness—singling out China as gaining ground—and declined to fully endorse the new CDC vaccine director, blending industry critique with public‑health ambivalence. His comments underscore tensions between political positioning and health policy messaging while rattling stakeholders who prefer facts over theatrical proclamations.
- Kennedy defensive in hearings, balancing White House and base (4)
- Kennedy hesitates on CDC director, vaccine reports spark debate (5)
- On Pharma frontlines: Kennedy warns China is eating our lunch (3)
- All Other Stories
Kennedy defensive in hearings, balancing White House and base
Kennedy hesitates on CDC director, vaccine reports spark debate
On Pharma frontlines: Kennedy warns China is eating our lunch
All Other Stories
Ciltacabtagene autoleucel in high-risk smoldering multiple myeloma: the CAR-PRISM phase 2 trial
Omar Nadeem / nature - Nature Medicine, Published online: 20 April 2026; doi:10.1038/s41591-026-04365-yAs presented at the 2026 AACR Annual Meeting, in a phase 2 trial, treatment of patients with high-risk smoldering multiple myeloma with BCMA-targeting CAR T cell therapy cilta…
AI Summary: The CAR-PRISM phase 2 study reports that ciltacabtagene autoleucel, a BCMA-directed CAR T therapy, produced meaningful responses in patients with high‑risk smoldering multiple myeloma, suggesting potential to delay progression to symptomatic disease and defer immediate treatment. Early results show promising efficacy with manageable toxicities, hinting at a shift toward treating disease earlier rather than later.
- CAR-PRISM results: compelling MRD negativity, potential treatment shift (4)
- Experts weigh in: praise, safety concerns, and clinical enthusiasm (4)
- Policy and IO context: regulation, immune engineering, industry implications (3)
- All Other Stories
CAR-PRISM results: compelling MRD negativity, potential treatment shift
Experts weigh in: praise, safety concerns, and clinical enthusiasm
Policy and IO context: regulation, immune engineering, industry implications
All Other Stories
Long-term Use of Immunotherapy May Be Safe for Patients With Alveolar Soft Part Sarcoma
Kathleen Medora / aacr - SAN DIEGO – Long-term adverse events were rare and manageable among patients with alveolar soft part sarcoma (ASPS), which primarily affects adolescents and young adults, who received immunotherapy beyond the standard two years, according to results from …
AI Summary: Observational data indicate extended checkpoint inhibitor therapy can be tolerated by patients with alveolar soft part sarcoma and may provide sustained disease control for many. The findings support considering prolonged treatment in select cases, while underscoring the need for vigilant monitoring for late toxicities and randomized trials to confirm benefit.
Improving oral care more than halves hospital-acquired pneumonia risk, major trial finds
medicalxpress - A landmark trial presented at ESCMID Global 2026 shows that improving oral hygiene for hospital patients can reduce the risk of non-ventilator-associated hospital-acquired pneumonia (NV-HAP) by 60%.
AI Summary: A major randomized trial found that simple improvements in oral care—regular toothbrushing and mouth hygiene—cut hospital‑acquired pneumonia risk by over half in hospitalized patients. The low‑cost intervention reduced respiratory complications and antibiotic use, suggesting wards could prevent serious infections with a toothbrush rather than another headline‑seeking drug.
E-bike and scooter crashes driving more brain injuries
medicalxpress - The growing use of electric bikes and scooters has caused a surge in brain and spine injuries among urban riders and pedestrians, a new study shows. Led by NYU Langone Health researchers, the study found that these injuries now account for nearly 7% of tr…
AI Summary: A new analysis links the rise of e‑bikes and scooters to a measurable increase in traumatic brain injuries and trauma admissions, accounting for roughly 7% of related cases in the examined data. Researchers urge better helmet uptake, infrastructure changes and policy action to curb preventable head injuries before cities regret their micro‑mobility love affair.
CDC: Proportion of extensively drug-resistant Shigella isolates increasing
medicalxpress - The proportion of extensively drug-resistant (XDR) Shigella isolates in the United States increased from 2011–2015 to 2023, according to research published in the April 9 issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality…
AI Summary: Federal health officials report a worrying uptick in extensively drug‑resistant Shigella strains, complicating treatment and raising the risk of harder‑to‑control outbreaks. The data underscore the need for enhanced surveillance, hygiene measures, antibiotic stewardship and rapid public‑health responses as standard antibiotics lose reliability. Try not to spread it—literally.
Should you really trust health advice from an AI chatbot?
bbc - Abi has had very mixed results when asking a chatbot for guidance about her health issues.
AI Summary: Recent analyses and a hospital study reveal mainstream AI chatbots frequently provide incorrect or misleading medical guidance and miss initial diagnoses, posing real patient‑safety risks. The research shows these systems can fabricate facts, overconfidently assert dubious recommendations and fail to flag uncertainty, prompting calls for clinician oversight, clearer warnings and tighter evaluation before trusting bots with health decisions.
- Chatbots misdiagnose and confidently give dangerous medical advice (4)
- Companies race to build clinical AI tools and invest heavily (4)
- Other AI healthcare stories: innovation, payers, workflows, mental health trials (12)
- Researchers demand proof and robust evaluation before clinical AI deployment (5)
- Utah pilots bold AI medical programs, sparking safety debates (3)
- All Other Stories
Chatbots misdiagnose and confidently give dangerous medical advice
Companies race to build clinical AI tools and invest heavily
Other AI healthcare stories: innovation, payers, workflows, mental health trials
Researchers demand proof and robust evaluation before clinical AI deployment
Utah pilots bold AI medical programs, sparking safety debates
All Other Stories
Three gene therapy pioneers just won the Breakthrough Prize. This is their story
Ryan Cross / endpoints - A trio of scientists behind the first gene therapy approved in the United States have been awarded a Breakthrough Prize in Life Sciences. It’s arguably one of the most prominent recognitions yet for the field ...
AI Summary: Three gene‑therapy researchers received the Breakthrough Prize in recognition of foundational work that enabled the first CRISPR-based sickle cell therapy. The award highlights decades of basic and translational research that turned genome editing from lab curiosity into a tangible clinical remedy, with winners sharing a multimillion‑dollar prize and public acclaim.
First-Line Zongertinib in Advanced HER2-Mutant NSCLC: A New Targeted Standard Begins to Take Shape
oncodaily - For years, HER2-mutant non-small-cell lung cancer sat in an uncomfortable place in thoracic oncology. It was clearly an oncogene-driven disease, but unlike EGFR-mutant or ALK-rearranged NSCLC, it did not have […]
AI Summary: Clinical trial data show zongertinib delivers strong antitumor activity as a first‑line treatment for patients with advanced HER2‑mutant non‑small cell lung cancer, positioning the drug as a potential new targeted standard. Robust response rates in previously untreated patients are prompting clinicians to rethink initial treatment choices while attention turns to long‑term safety and access.
Growing liver tissue directly in the body could ease donor organ shortage
medicalxpress - In patients developing end-stage liver disease, the damage has become too severe for the liver's normally extraordinary regenerative capacity to repair or compensate for it. Once this "point of no return" has been reached, the only option is an organ tran…
AI Summary: Scientists report a technique to grow liver tissue directly inside the body as a potential solution to donor organ shortages, demonstrating functional hepatic tissue formation in preclinical or early clinical models. The promising results have been followed by an editorial expression of concern over methodology and data, prompting calls for independent validation before wider clinical use.